Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results Press Release
American Neurological Association (ANA) Annual Meeting October 18, 2026 Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis: Results of the MaGic Study Open-label Extension 1.3 MB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.3 MB Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.3 MB American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 1.3 MB CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (poster) 1.5 MB Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.4 MB CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (slides) 579 KB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.4 MB American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB 18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.3 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB Minimal Symptom Expression With Claseprubart, an Active C1S Inhibitor, in Patients With Generalized Myasthenia Gravis 1.4 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB Congress of the European Academy of Neurology (EAN) 2026 June 27, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.4 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.6 MB Peripheral Nerve Society (PNS) June 13, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.5 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.5 MB American Association of Neurology (AAN) 2026 April 20, 2026 Top-line Results for MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis 594.2 KB Proximal Complement Inhibition in Generalized Myasthenia Gravis 716 KB Muscular Dystrophy Association (MDA) Clinical & Scientific Conference March 8, 2026 Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.5 MB Minimal Symptom Expression (MSE) with Active C1s Inhibition with Claseprubart 1.6 MB Top-Line Results from MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis 1.4 MB American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting October 29, 2025 Top-line results for MaGic, a phase 2 trial of claseprubart (DNTH103), an active C1s inhibitor, in generalized myasthenia gravis 681.2 KB 18th International Congress on Neuromuscular Diseases (ICNMD) October 25, 2024 DNTH103 shows sustainable inhibition of complement and prevents nerve conduction velocity impairment in a preclinical model of CIDP 7.6 MB DNTH103 shows sustainable inhibition of complement and prevents nerve conduction velocity impairment in a preclinical model of CIDP 10 MB Pagination Current page 1 Page 2 Next page › Last page »
American Neurological Association (ANA) Annual Meeting October 18, 2026 Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis: Results of the MaGic Study Open-label Extension 1.3 MB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.3 MB Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.3 MB
Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis: Results of the MaGic Study Open-label Extension 1.3 MB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.3 MB Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.3 MB
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting September 29, 2026 Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 1.3 MB CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (poster) 1.5 MB Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.4 MB CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (slides) 579 KB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.4 MB
Sustained Safety and Efficacy Profile of Active C1s Inhibitor Claseprubart in Patients with Generalized Myasthenia Gravis 1.3 MB CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (poster) 1.5 MB Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.4 MB CAPTIVATE Interim Analysis: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (slides) 579 KB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.4 MB
American Academy of Neurology (AAN) Autoimmune Neurology Conference August 7, 2026 Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB
Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.7 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 566.7 KB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 2.3 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 2.3 MB Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 2.7 MB
18th International Congress on Neuromuscular Diseases (ICNMD) July 7, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.3 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB Minimal Symptom Expression With Claseprubart, an Active C1S Inhibitor, in Patients With Generalized Myasthenia Gravis 1.4 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB
Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.3 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB Minimal Symptom Expression With Claseprubart, an Active C1S Inhibitor, in Patients With Generalized Myasthenia Gravis 1.4 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB
Congress of the European Academy of Neurology (EAN) 2026 June 27, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.4 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.6 MB
Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.4 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.4 MB Safety and Efficacy of Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.5 MB Minimal Symptom Expression with Claseprubart, an Active C1s Inhibitor, in Patients with Generalized Myasthenia Gravis 1.6 MB
Peripheral Nerve Society (PNS) June 13, 2026 Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.5 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.5 MB
Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis: Upstream Versus Downstream Complement Blockade 1.5 MB CAPTIVATE Trial Design: A Pivotal Phase 3 Study of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy 1.5 MB
American Association of Neurology (AAN) 2026 April 20, 2026 Top-line Results for MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis 594.2 KB Proximal Complement Inhibition in Generalized Myasthenia Gravis 716 KB
Top-line Results for MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis 594.2 KB Proximal Complement Inhibition in Generalized Myasthenia Gravis 716 KB
Muscular Dystrophy Association (MDA) Clinical & Scientific Conference March 8, 2026 Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.5 MB Minimal Symptom Expression (MSE) with Active C1s Inhibition with Claseprubart 1.6 MB Top-Line Results from MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis 1.4 MB
Upstream Versus Downstream Complement Blockade: Potential Mechanistic Advantages of aC1s Targeting in Myasthenia Gravis 1.5 MB Minimal Symptom Expression (MSE) with Active C1s Inhibition with Claseprubart 1.6 MB Top-Line Results from MaGic, a Phase 2 Trial of Claseprubart (DNTH103), an Active C1s Inhibitor, in Generalized Myasthenia Gravis 1.4 MB
American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) 2025 Annual Meeting October 29, 2025 Top-line results for MaGic, a phase 2 trial of claseprubart (DNTH103), an active C1s inhibitor, in generalized myasthenia gravis 681.2 KB
Top-line results for MaGic, a phase 2 trial of claseprubart (DNTH103), an active C1s inhibitor, in generalized myasthenia gravis 681.2 KB
18th International Congress on Neuromuscular Diseases (ICNMD) October 25, 2024 DNTH103 shows sustainable inhibition of complement and prevents nerve conduction velocity impairment in a preclinical model of CIDP 7.6 MB DNTH103 shows sustainable inhibition of complement and prevents nerve conduction velocity impairment in a preclinical model of CIDP 10 MB
DNTH103 shows sustainable inhibition of complement and prevents nerve conduction velocity impairment in a preclinical model of CIDP 7.6 MB DNTH103 shows sustainable inhibition of complement and prevents nerve conduction velocity impairment in a preclinical model of CIDP 10 MB
